Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on lipid and lipoprotein metabolism. United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction.
A 1-year longitudinal multicenter study was undertaken to monitor the effects on lipid metabolism of two once-a-month injectable contraceptive preparations, Mesigyna (50 mg norethisterone enanthate and 5 mg estradiol valerate and Cyclofem (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate). A total of 357 volunteers from four centers (Hangzhou, Havana, Jakarta, and Shanghai) were monitored during one pretreatment cycle, the third and ninth injection intervals, and during one post-treatment cycle, approximately 3 months after the 9-month period of treatment was completed. With both preparations, changes were observed at 3 months of use, remained essentially unchanged during treatment, and returned to pretreatment levels after discontinuation of use. With Mesigyna, changes consisted mostly of decreases in high density lipoprotein cholesterol (HDL-C, -10%), apolipoprotein AI (-9%), and triglycerides (-15%). With Cyclofem, changes were even smaller. With both, variations in lipid levels mirrored closely the pharmacokinetics of each preparation and the biphasic nature of the injection intervals.
D000328:Adult; D002784:Cholesterol / Q000097:blood; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000494:pharmacology*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000494:pharmacology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008137:Longitudinal Studies; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000494:pharmacology*; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides; C418365:estradiol, norethindrone drug combination; D004958:Estradiol; C034528:CycloProvera; D002784:Cholesterol; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone